首站-论文投稿智能助手
典型文献
C0818,a novel curcumin derivative,induces ROS-dependent cytotoxicity in human hepatocellular carcinoma cells in vitro via disruption of Hsp90 function
文献摘要:
Heat shock protein 90(Hsp90)is the most common molecular chaperone that controls the maturation of many oncoproteins critical in tumor development.Hsp90 has been considered as a promising target for cancer treatment,but the clinical significance of Hsp90 and the mechanisms of Hsp90 regulating the tumor-promoting effects in hepatocellular carcinoma(HCC)remain obscure.Previous studies have shown that curcumin,a polyphenol derived from the plant turmeric(Curcuma longa),inhibits tumor growth,which may provide an effective alternative therapy for HCC.Compared to curcumin,a novel derivative of curcumin,3,5-(E)-Bis(3-methoxy-4-hydroxybenzal)-4-piperidinone hydrochloride(C0818)that is more potent in Hsp90 inhibition and antitumor activity.In this study,we investigated the effect of C0818 on HCC cells in vitro and its relation to Hsp90 inhibition.We showed that C0818 concentration-dependently inhibited the proliferation,the colony formation and induced apoptosis in HepG2 and Sk-Hep-1 cells.C0818 concentration-dependently inhibited DNA synthesis and induced G2/M phase arrest in HepG2 and Sk-Hep-1 cells.We further demonstrated that C0818 induced ROS-and caspase-dependent apoptosis in HCC cells through the mitochondrial-mediated pathway.C0818 induced the degradation of Hsp90 client proteins as RAS,C-Raf,P-C-Raf,Erk,P-ERK,MEK,P-MEK,Akt and P-Akt,which led to subsequent inhibition of the RAS/RAF/MEK/ERK and PI3K/AKT pathways.We revealed that C0818 could inhibit the binding of Hsp90 with its clients without affecting their transcription,which subsequently induced the degradation of Hsp90 clients by the proteasome rather than the lysosome.These results are of potential importance for elucidating a novel Hsp90 inhibitor targeting HCC.
文献关键词:
作者姓名:
Ahmed Attia Ahmed Abdelmoaty;Ping Zhang;Wen Lin;Ying-juan Fan;Sheng-nan Ye;Jian-hua Xu
作者机构:
Department of Pharmacology,School of Pharmacy,Fujian Provincial Key Laboratory of Natural Medicine Pharmacology,Fujian Medical University,Fuzhou 350122,China;The First Affiliated Hospital of Fujian Medical University,Fuzhou 350004,China
引用格式:
[1]Ahmed Attia Ahmed Abdelmoaty;Ping Zhang;Wen Lin;Ying-juan Fan;Sheng-nan Ye;Jian-hua Xu-.C0818,a novel curcumin derivative,induces ROS-dependent cytotoxicity in human hepatocellular carcinoma cells in vitro via disruption of Hsp90 function)[J].中国药理学报(英文版),2022(02):446-456
A类:
C0818,oncoproteins,hydroxybenzal,piperidinone
B类:
novel,curcumin,derivative,induces,ROS,cytotoxicity,human,hepatocellular,carcinoma,cells,vitro,via,disruption,Hsp90,function,Heat,shock,most,common,molecular,chaperone,that,controls,maturation,many,critical,development,been,considered,promising,cancer,treatment,but,clinical,significance,mechanisms,regulating,promoting,effects,HCC,remain,obscure,Previous,studies,have,shown,polyphenol,derived,from,plant,turmeric,Curcuma,longa,inhibits,growth,which,may,provide,effective,alternative,therapy,Compared,Bis,methoxy,hydrochloride,more,inhibition,antitumor,activity,In,this,study,investigated,relation,We,showed,concentration,dependently,inhibited,proliferation,colony,formation,induced,apoptosis,HepG2,Sk,synthesis,phase,arrest,further,demonstrated,caspase,through,mitochondrial,mediated,degradation,RAS,Raf,Erk,ERK,MEK,Akt,RAF,PI3K,AKT,pathways,revealed,could,binding,clients,without,affecting,their,transcription,subsequently,by,proteasome,rather,than,lysosome,These,results,potential,importance,elucidating,inhibitor,targeting
AB值:
0.48998
相似文献
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
Xinyi Zhou;Qian Xiao;Dongliang Fu;Haochen Zhang;Yang Tang;Jinjie He;Yeting Hu;Xiangxing Kong;Fei Teng;Xiangrui Liu;Ying Yuan;Kefeng Ding-Department of Colorectal Surgery and Oncology,Key Laboratory of Cancer Prevention and Intervention,Ministry of Education,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Medical Oncology,Key Laboratory of Cancer Prevention and Intervention,Ministry of Education,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Hangzhou Oncocare Co Ltd,Hangzhou 310009,China;Department of Pharmacology,Zhejiang University School of Medicine,Hangzhou 310058,China;Cancer Center,Zhejiang University,Hangzhou 310009,China
PGK1-coupled HSP90 stabilizes GSK3β expression to regulate the stemness of breast cancer stem cells
Wei Tang;Yu Wu;Xin Qi;Rilei Yu;Zhimin Lu;Ao Chen;Xinglong Fan;Jing Li-Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China;Department of Hepatobiliary and Pancreatic Surgery and Zhejiang Provincial Key Laboratory of Pancreatic Disease of the First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University, Hangzhou 310029, China;Department of Thoracic Surgery, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao 266003, China;Open Studio for Druggability Research of Marine Natural Products, Pilot National Laboratory for Marine Science and Technology (Qingdao), Qingdao 266003, China;Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao 266003, China
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription
Xiaoqing Lu;Liwei An;Guangjian FanTi;Lijuan Zang;Weiyi Huang;Junjian Li;Jun Liu;Weiyu Ge;Yuwei Huang;Jingxuan Xu;Shaoqian Du;Yuan Cao;Tianhao Zhou;Huijing Yin;Li Yu;Shi Jiao;Hongxia Wang-State Key Laboratory of Oncogenes and Related Genes,Department of Oncology,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,China;Department of Breast Surgery,Shanxi Cancer Hospital,Chinese Academy of Medical Sciences,Taiyuan,Shanxi,China;Department of Medical Ultrasound,Shanghai Tenth People's Hospital,Tongji University Cancer Center,School of Medicine,Tongji University,Shanghai,China;Precision Research Center for Refractory Diseases,Institute for Clinical Research,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,China;Department of Pathology,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,China;State Key Laboratory of Membrane Biology,Tsinghua-Peking University Joint Center for Life Sciences,School of Life Science,Tsinghua University,Beijing,China;State Key Laboratory of Genetic Engineering,School of Life Sciences,Fudan University,Shanghai,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis
Shoubin Zhan;Ping Yang;Shengkai Zhou;Ye Xu;Rui Xu;Gaoli Liang;Chenyu Zhang;Xi Chen;Liuqing Yang;Fangfang Jin;Yanbo Wang-Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy,State Key Laboratory of Pharmaceutical Biotechnology and Department of Physiology,Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology,NJU Advanced Institute of Life Sciences(NAILS),School of Life Sciences,Nanjing University,Nanjing 210023,China;Department of Clinical Laboratory,The Affiliated Drum Tower Hospital of Nanjing University Medical School,Nanjing 210023,China;Department of Infectious Diseases,The First People's Hospital of Lianyungang,The First Affiliated Hospital of Kangda College of Nanjing Medical University,Lianyungang 222000,China;School of Medicine&Holistic Integrative Medicine,Nanjing University of Chinese Medicine,Nanjing 210023,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。